Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Marino Garcia says small biotech carries more risk than Big Pharma but it gives people empowerment and visible daily impact. Dianthus competes by focusing every day on moving faster, and he says investors praise the company for doing everything it promised and more. That execution comes back to hiring the right team.

Related Insights

Large pharmaceutical corporations possess the capital to advance dozens of therapeutic areas simultaneously, but small biotechs achieve velocity through strict specialization. Startups move faster through necessity by focusing their entire workforce on a single clinical challenge, feeding large pharma pipelines through partnerships.

Marino Garcia says Big Pharma has scale for large multinational trials and global launches. But he argues biotech's edge is strategic focus, execution, and speed, and with investor support Dianthus can do what a Big Pharma can do and do it better. That focus, he says, matters.

A seasoned pharma exec describes the transition to biotech, highlighting that the reduced complexity and faster pace are not just efficient but 'invigorating.' This speed allows for instantaneous, data-driven decisions on the fly, empowering teams to move much more quickly toward clinical goals and patient impact compared to the complex layers of large pharma.

The motivation for a senior leader to leave a stable pharma career for a risky biotech is often mission-driven. The primary driver is the ability to leverage a focused technology to address patient unmet needs with greater speed, bypassing the complexities of large organizations. It's about a clearer and quicker line-of-sight to the clinic and to patients.

In the rare disease space, success hinges on deep patient community engagement. Smaller, nimbler biotechs often excel at creating these essential personal ties, giving them a significant advantage over larger pharmaceutical companies.

The primary operational difference between biotech and big pharma isn't just budget size, but how resource constraints force radical prioritization. The entire biotech organization must align on three or four critical, needle-moving goals tied to the next financing catalyst, a level of focus often diffused in larger companies.

Contrary to most industries, scale is not a decisive advantage in drug discovery. Wellington's Jean Hynes notes that small, nimble biotech companies discover roughly half of all new drugs. This creates a perpetual opportunity for investors to back small firms that can generate massive value.

For small biotechs, the playbook for success extends beyond scientific discovery. It requires creativity and innovation in the operational process itself—finding efficient paths through regulatory checkpoints, securing non-traditional funding, and leveraging external resources to advance development with limited capital.

Small biotechs face a paradox: they must pursue highly innovative, risky science to differentiate themselves, as "me-too" drugs won't attract investment. The key to survival is managing this high scientific risk with strategies that provide fast, capital-efficient data for go/no-go decisions.

Iolyx Therapeutics' CEO notes the surprising capital efficiency of lean biotech. Her team advanced a drug from discovery through Phase 2 for approximately $20 million—an amount she could have easily spent on a single marketing campaign at Genentech. This highlights the operational leverage of focused, small teams.

Small biotechs beat big pharma through daily execution | RiffOn